Vertex Pharmaceuticals Inc VRTX:NASDAQ

Last Price$173.59NASDAQ Previous Close - Last Trade as of 4:00PM ET 10/14/19

Today's Change+1.18(0.68%)
Bid (Size)$171.33 (1)
Ask (Size)$177.87 (1)
Day Low / High$172.32 - 175.25
Volume579.6 K

Vertex Pharma to Seek Approvals for Triple Combination of VX-445, Tezacaftor and Ivacaftor in Cystic Fibrosis - Stock Up 2%

1:29PM ET 5/30/2019 MT Newswires
Vertex Pharmaceuticals (VRTX) said on Thursday it has selected the triple combination of the next-generation corrector VX-445, tezacaftor and ivacaftor to submit for potential global regulatory approvals for people ages 12 and older with cystic fibrosis (CF) following positive outcomes from its trials.

"The substantial improvements in lung function and other measures of CF seen in these Phase 3 studies are unprecedented and represent a defining moment in the journey to provide medicines that treat the underlying cause of CF to the vast majority of people with CF," said Steven Rowe of University of Alabama.

Vertex plans to submit a New Drug Application to the US Food and Drug Administration in Q3 of 2019 and a Marketing Authorization Application to the European Medicines Agency in Q4.

Price: 169.49, Change: +2.94, Percent Change: +1.77